Study of PLB1004 with chemotherapy for EGFR-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called PLB1004 combined with standard chemotherapy for people with non-small cell lung cancer (NSCLC) that has an EGFR mutation. The goal is to see if this combination can help shrink or control the cancer and whether it can be used before surgery for earlier-stage disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer that cannot be removed with surgery or has spread to other parts of the body, or certain patients with resectable stage II-III cancer are also being studied.
- Your tumor must have an EGFR mutation (a specific change in the cancer cells), which will be confirmed by a tissue, fluid, or blood test.
- If you have already had treatment, you must have progressed or not tolerated it. If you received first-generation EGFR inhibitors, you must test negative for the T790M mutation.
- You must be well enough to have a performance status of 0 or 1 (you can do your normal activities with little or no help).
- Your organ functions (blood, liver, kidneys, and blood clotting) must be within acceptable ranges.
- If you are in the surgical group, you must be able to tolerate lung surgery as assessed by a surgeon.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (Vebreltinib and PLB1004) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has developed MET amplification or overexpression after previous EGFR-targeted therapy. The goal is to see if this combination can help shrink tumors or slow their growth.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This trial tests PLB1004, an oral medication that targets a specific gene mutation (EGFR) in non-small cell lung cancer. It may be an option if you have this mutation and are looking for a new treatment.
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
This study tests a new drug, ANS014004, combined with an EGFR-TKI (a targeted therapy) for people with advanced non-small cell lung cancer that has EGFR mutations. The aim is to see if the combination is safe and effective in slowing the cancer's growth.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.